BBIO vs. CRL: BridgeBio Pharma vs. Charles River Laboratories Stock Comparison

Company Profile

BridgeBio Pharma (BBIO) and Charles River Laboratories (CRL) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BBIO is classified in Biotechnology while CRL is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Charles River Laboratories (CRL) earns 1.27% on shareholders’ equity, ranked against its industry; BridgeBio Pharma (BBIO) has no ROE this period.

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Charles River Laboratories (CRL) reports 1.01%, ranking against industry peers normally.

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Charles River Laboratories (CRL) reports 23.42%, ranking against industry peers normally.

Profitability Metrics

Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Charles River Laboratories (CRL) at -0.85% is in the bottom quartile, showing a clear gap in revenue momentum.

Only one side can be read here: Charles River Laboratories (CRL) reports EPS growth of -1,555.00%, ranked against its industry; BridgeBio Pharma (BBIO) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both BridgeBio Pharma (BBIO) at 2.09 and Charles River Laboratories (CRL) at 1.41 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Only one side’s leverage can be read here: Charles River Laboratories (CRL) carries debt-to-equity ratio of 0.87 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

Financial Strength Metrics

Dividends

Neither BridgeBio Pharma (BBIO) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither BridgeBio Pharma (BBIO) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Charles River Laboratories (CRL) trades at 366.87 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

On P/S ratio, both BridgeBio Pharma (BBIO) at 15.31 and Charles River Laboratories (CRL) at 4.07 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Charles River Laboratories (CRL) reports 5.01, ranking against industry peers normally.

Valuation Metrics